The somatostatin analogue octreotide inhibits angiogenesis in the earliest, but not in advanced, stages of portal hypertension in rats

Journal of Cellular and Molecular Medicine

Volumn 12, Issue 5A, 2008, Pages 1690-1699

  Mejias, Marc ^a   Garcia Pras, Ester ^a   Tiani, Carolina ^a   Bosch, Jaime ^a   Fernandez, Mercedes ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Angiogenesis; Heme oxygenase; Octreotide; Portal hypertension; Somatostatin

Indexed keywords

DRUG DERIVATIVE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HEME OXYGENASE 1; NOS3 PROTEIN, RAT; OCTREOTIDE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; SSTR2 PROTEIN, RAT; VASCULOTROPIN A;

ANIMAL; ARTICLE; CHEMISTRY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HEMODYNAMICS; MALE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PORTAL HYPERTENSION; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; GENE EXPRESSION REGULATION; HEME OXYGENASE-1; HEMODYNAMICS; HYPERTENSION, PORTAL; MALE; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE SYNTHASE TYPE III; OCTREOTIDE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

RATTUS;

EID: 54049148148     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00218.x     Document Type: Article

References (30)

1. Bosch J, Pizcueta P, Feu F, Fernandez M, Garcia-Pagan JC. Pathophysiology of portal hypertension. Gastroenterol Clin North Am. 1992 21 : 1 13.
2. Fernandez M, Vizzutti F, Garcia-Pagan JC, Rodes J, Bosch J. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology. 2004 126 : 886 94.
3. Fernandez M, Mejias M, Angermayr B, Garcia-Pagan JC, Rodes J, Bosch J. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol. 2005 43 : 98 103.
4. Fernandez M, Mejias M, Garcia-Pras E, Mendez R, Garcia-Pagan JC, Bosch J. Reversal of portal hypertension and hyper-dynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. Hepatology. 2007 46 : 1208 17.
5. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999 20 : 157 98.
6. Abraldes JG, Bosch J. Somatostatin and analogues in portal hypertension. Hepatology. 2002 35 : 1305 12.
7. Woltering EA, Barrie R, O'Dorisio TM, Arce D, Ure T, Cramer A, Holmes D, Robertson J, Fassler J. Somatostatin ana-logues inhibit angiogenesis in the chick chorioallantoic membrane. J Surg Res. 1991 50 : 245 51.
8. Danesi R, Agen C, Benelli U, Paolo AD, Nardini D, Bocci G, Basolo F, Campagni A, Tacca MD. Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). Clin Cancer Res. 1997 3 : 265 72.
9. Dasgupta P. Somatostatin analogues: Multiples roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther. 2004 102 : 61 85.
10. Woltering EA, Watson JC, Alperin-Lea RC, Sharma C, Keenan E, Kurozawa D, Barrie R. Somatostatin analogs: angiogen-esis inhibitors with novel mechanisms of action. Invest New Drugs. 1997 15 : 77 86.
11. Lamberts SW, de Herder WW, Hofland LJ. Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrinol Metab. 2002 13 : 451 7.
12. Woltering EA. Development of targeted somatostatin-based antiangiogenic therapy: a review and future perspectives. Cancer Biother Radiopharm. 2003 18 : 601 9.
13. Raynor K, Murphy WA, Coy DH, Taylor JE, Moreau JP, Yasuda K, Bell GI, Reisine T. Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides. Mol Pharmacol. 1993 43 : 838 44.
14. Fernandez M, Garcia-Pagan JC, Casadevall M, Bernadich C, Piera C, Whittle BJ, Pique JM, Bosch J, Rodes J. Evidence against a role for inducible nitric oxide synthase in the hyperdynamic circulation of portal hypertensive rats. Gastroenterology. 1995 108 : 1487 95.
15. Fernandez M, Garcia-Pagan JC, Casadevall M, Mourelle MI, Pique JM, Bosch J, Rodes J. Acute and chronic cyclooxygenase blockade in portal-hypertensive rats: influence on nitric oxide biosynthesis. Gastroenterology. 1996 110 : 1529 35.
16. Buscail L, Saint-Laurent N, Chastre E, Vaillant JC, Gespach C, Capella G, Kalthoff H, Lluis F, Vaysse N, Susini C. Loss of sst2 somatostatin receptor gene expression in human pancreatic and col-orectal cancer. Cancer Res. 1996 56 : 1823 7.
17. Reubi J, Horisberger U, Essed CE, Jeekel J, Klijn JG, Lamberts SW. Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas. Gastro-enterology. 1988 95 : 760 3.
18. Lambooij AC, Kuijpers RWAM, van Lichtenauer-Kaligis EGR, Kliffen M, Baarsma GS, van Hagen PM, Mooy CM. Somatostatin receptor 2A expression in choroidal neovascularization secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci. 2000 41 : 2329 35.
19. Fernandez M, Bonkovsky HL. Increased heme oxygenase-1 gene expression in liver cells and splanchnic organs from portal hypertensive rats. Hepatology. 1999 29 : 1672 9.
20. Fernandez M, Lambrecht RW, Bonkovsky HL. Increased heme oxygenase activity in splanchnic organs from portal hypertensive rats: role in modulating mesenteric vascular reactivity. J Hepatol. 2001 34 : 812 7.
21. Lambrecht RW, Fernandez M, Shan Y, Bonkovsky HL. Heme oxygenase in portal hypertension and liver disease. In : Gines P, Arroyo V, Rodes J, Schrier RW, editors. Ascites and Renal Dysfunction in Liver Disease. Pathogenesis, Diagnosis, and Treatment. Blackwell Publishing Malden, MA 2005. pp. 125 36.
22. Angermayr B, Mejias M, Gracia-Sancho J, Garcia-Pagan JC, Bosch J, Fernandez M. Heme oxygenase attenuates oxidative stress and inflammation, and increases VEGF expression in portal hypertensive rats. J Hepatol. 2006 44 : 1033 9.
23. Angermayr B, Fernandez M, Mejias M, Gracia-Sancho J, Garcia-Pagan JC, Bosch J. NAD(P)H oxidase modulates angiogenesis and the development of por-tosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats. Gut. 2007 56 : 560 4.
24. Abbasoglu SD, Erbil Y, Eren T, Giris M, Barbaros U, Yucel R, Olgac V, Uysal M, Toker G. The effects of heme oxygenase-1 induction by octreotide on radiation enteritis. Peptides. 2006 27 : 1570 6.
25. Erbil Y, Giris M, Abbasoglu SD, Barbaros U, Yanik BT, Necefli A, Olgac V, Toker GA. Effect of heme oxygenase-1 induction by octreotide on TNBS-induced colitis. J Gastroenterol Hepatol. 2007 22 : 1852 8.
26. Paran D, Paran H. Somatostatin analogs in rheumatoid arthritis and other inflammatory and immune-mediated condi-tions. Curr Opin Invest Drugs. 2003 4 : 578 82.
27. Yang YY, Lin HC, Huang YT, Lee TY, Lee WC, Hou MC, Lee FY, Chang FY, Lee SD. Adaptive vasodilatory response after octreotide treatment. Am J Physiol Gastrointest Liver Physiol. 2001 281 : G117 23.
28. Elbirt KK, Bonkovsky HL. Heme oxyge-nase: recent advances in understanding its regulation and role. Proc Assoc Am Physicians. 1999 111 : 438 47.
29. Fernandez M, Bonkovsky HL. Vascular endothelial growth factor increases heme oxygenase-1 protein expression in the chick embryo chorioallantoic membrane. Br J Pharmacol. 2003 139 : 634 40.
30. Cirera I, Feu F, Luca A, Garcia-Pagan JC, Fernandez M, Escorsell A, Bosch J, Rodes J. Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: a double-blind hemodynamic investigation. Hepatology. 1995 22 : 106 11.